Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 10Lymphoma 10Lymphoma, Follicular 7Recurrence 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, Mantle-Cell 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

ibrutinib 3Vincristine 2Methotrexate 2tozasertib 1thymoglobulin 1romiplostim 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1lucatumumab 1fludarabine 1fenebrutinib 1enzastaurin 1duvelisib 1Receptors, Chimeric Antigen 1Prednisone 1Prednisolone 1Hydrocortisone 1Hu-Mik-beta-1 monoclonal antibody 1Doxorubicin 1Dasatinib 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphoid × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡